JP2016523893A5 - - Google Patents

Download PDF

Info

Publication number
JP2016523893A5
JP2016523893A5 JP2016522952A JP2016522952A JP2016523893A5 JP 2016523893 A5 JP2016523893 A5 JP 2016523893A5 JP 2016522952 A JP2016522952 A JP 2016522952A JP 2016522952 A JP2016522952 A JP 2016522952A JP 2016523893 A5 JP2016523893 A5 JP 2016523893A5
Authority
JP
Japan
Prior art keywords
amine
quinolin
group
hydrogen atom
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016522952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523893A (ja
JP6895251B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/062849 external-priority patent/WO2015001518A1/en
Publication of JP2016523893A publication Critical patent/JP2016523893A/ja
Publication of JP2016523893A5 publication Critical patent/JP2016523893A5/ja
Application granted granted Critical
Publication of JP6895251B2 publication Critical patent/JP6895251B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016522952A 2013-07-05 2014-07-04 レトロウイルスにより引き起こされる疾患を処理する為に有用な化合物 Active JP6895251B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361843155P 2013-07-05 2013-07-05
US61/843,155 2013-07-05
PCT/IB2014/062849 WO2015001518A1 (en) 2013-07-05 2014-07-04 Bicyclic compounds useful for treating diseases caused by retroviruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019086240A Division JP2019142946A (ja) 2013-07-05 2019-04-26 レトロウイルスにより引き起こされる疾患を処理する為に有用な化合物

Publications (3)

Publication Number Publication Date
JP2016523893A JP2016523893A (ja) 2016-08-12
JP2016523893A5 true JP2016523893A5 (enExample) 2017-07-06
JP6895251B2 JP6895251B2 (ja) 2021-06-30

Family

ID=51453778

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016522952A Active JP6895251B2 (ja) 2013-07-05 2014-07-04 レトロウイルスにより引き起こされる疾患を処理する為に有用な化合物
JP2019086240A Pending JP2019142946A (ja) 2013-07-05 2019-04-26 レトロウイルスにより引き起こされる疾患を処理する為に有用な化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019086240A Pending JP2019142946A (ja) 2013-07-05 2019-04-26 レトロウイルスにより引き起こされる疾患を処理する為に有用な化合物

Country Status (16)

Country Link
US (1) US9827237B2 (enExample)
EP (1) EP3016656B1 (enExample)
JP (2) JP6895251B2 (enExample)
KR (1) KR102326068B1 (enExample)
CN (1) CN105530938B (enExample)
AU (1) AU2014285733B2 (enExample)
BR (1) BR112016000127B1 (enExample)
CA (1) CA2916623C (enExample)
ES (1) ES2898385T3 (enExample)
HR (1) HRP20211839T1 (enExample)
MX (1) MX382692B (enExample)
PL (1) PL3016656T3 (enExample)
PT (1) PT3016656T (enExample)
RU (1) RU2681943C9 (enExample)
WO (1) WO2015001518A1 (enExample)
ZA (1) ZA201600317B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3059591A1 (en) * 2015-02-23 2016-08-24 Abivax Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
EP3058940A1 (en) * 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection
EP3059236A1 (en) * 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
KR20170109160A (ko) 2016-03-18 2017-09-28 현대자동차주식회사 엔진마운트의 체결구조
ES2846833T3 (es) 2016-07-18 2021-07-29 Janssen Pharmaceutica Nv Ligandos de obtención de imágenes de tau por PET
EP3594206A1 (en) * 2018-07-09 2020-01-15 Abivax Phenyl-n-quinoline derivatives for treating a rna virus infection
EP3594205A1 (en) 2018-07-09 2020-01-15 Abivax Phenyl-n-aryl derivatives for treating a rna virus infection
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
PL3999493T3 (pl) 2019-07-19 2024-04-22 Abivax Pochodne arylo-N-arylowe do leczenia zakażenia wirusem RNA
EP3848356A1 (en) * 2020-01-07 2021-07-14 Abivax Aryl-n-aryl derivatives for treating a rna virus infection
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
BR112023000047A2 (pt) 2020-07-02 2023-03-14 Incyte Corp Compostos de ureia tricíclicos como inibidores da v617f da jak2
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk﹘5抑制劑和彼之用途
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
MX2023013972A (es) 2021-05-27 2023-12-11 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto de quinolinamina, metodo de preparacion y aplicacion del mismo en productos farmaceuticos.
KR20240163688A (ko) 2022-03-17 2024-11-19 인사이트 코포레이션 Jak2 v617f 억제제로서의 삼환계 우레아 화합물
CN116120282B (zh) * 2022-08-04 2024-02-20 苏州系统医学研究所 具有ev71和/或cva16病毒抑制活性的化合物及其应用
JP2025538576A (ja) 2022-11-25 2025-11-28 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 キノリンアミン系化合物の結晶型及びその調製方法
CN118373771A (zh) 2023-01-20 2024-07-23 江苏柯菲平医药股份有限公司 一种喹啉衍生化合物或其可药用的盐及其制备方法和应用
AU2024334442A1 (en) * 2023-08-30 2026-03-05 Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. Compound for regulating activity of microrna-124

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB585362A (en) 1944-08-31 1947-02-05 Francis Henry Swinden Curd New heterocyclic compounds
BE486034A (enExample) 1947-11-28
DE958647C (de) 1952-12-28 1957-02-21 Hoechst Ag Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen
FR2387229A1 (fr) 1977-04-13 1978-11-10 Anvar Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
FR2436786A1 (fr) 1978-09-21 1980-04-18 Anvar Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments
FR2627493B1 (fr) 1988-02-23 1991-10-31 Sanofi Sa Procede de preparation de derives d'isoquinoleine
FR2645861A1 (fr) 1989-04-17 1990-10-19 Inst Nat Sante Rech Med Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
EP1165064B1 (en) 1999-04-05 2004-02-25 City of Hope Novel inhibitors of formation of advanced glycation endproducts (age's)
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
DE10013318A1 (de) 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
WO2002074726A2 (en) 2001-01-22 2002-09-26 Memory Pharmaceuticals Corporation Aniline derivatives useful as phosphodiesterase 4 inhibitors
PL375552A1 (en) 2002-05-22 2005-11-28 Amgen Inc. Vanilloid receptor ligands and their medical applications
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
CA2492907A1 (en) 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
WO2006081444A2 (en) 2005-01-28 2006-08-03 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
FR2849474B3 (fr) 2002-12-27 2004-12-03 Olivier Jean Noel Juin Installation de transformation de l'energie cinetique d'un fluide en energie electrique
WO2004078731A1 (en) 2003-03-06 2004-09-16 'chemical Diversity Research Institute', Ltd. Quinoline-carboxylic acids and the derivatives thereof, a focused library
FR2859475A1 (fr) 2003-09-04 2005-03-11 Centre Nat Rech Scient Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
FR2859474B1 (fr) 2003-09-04 2006-01-13 Centre Nat Rech Scient Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
NZ547481A (en) 2003-11-19 2009-12-24 Array Biopharma Inc Heterocyclic inhibitors of mek and methods of use thereof
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
US8030487B2 (en) 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
BRPI0806898A2 (pt) 2007-01-19 2015-07-14 Ardea Biosciences Inc Inibidores de mek
FR2912745A1 (fr) 2007-02-19 2008-08-22 Centre Nat Rech Scient Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
CA2681481A1 (en) 2007-03-16 2008-09-25 Mount Sinai School Of Medicine Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction
KR100961821B1 (ko) 2007-05-17 2010-06-08 주식회사 엘지화학 신규한 안트라센 유도체 및 이를 이용한 유기전자소자
AU2008286760A1 (en) 2007-08-15 2009-02-19 Memory Pharmaceuticals Corporation 3' substituted compounds having 5-HT6 receptor affinity
WO2009029617A1 (en) 2007-08-27 2009-03-05 Kalypsys, Inc. Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors
FR2926297B1 (fr) 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
FI2440546T3 (fi) * 2009-06-12 2023-03-30 Abivax Ennenaikaisen vanhenemisen ja erityisesti progerian hoitamiseen hyödyllisiä yhdisteitä
EP2266972A1 (en) * 2009-06-12 2010-12-29 Splicos New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
US8962583B2 (en) 2009-06-25 2015-02-24 The Brigham And Women's Hospital, Inc. Treatment of inflammatory diseases using miR-124
EP2465502A1 (en) 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
JP2016504268A (ja) * 2012-10-04 2016-02-12 オヤジェン インコーポレイテッドOyaGen, Inc. Vifの自己会合を撹乱する抗hiv剤としての小分子及びその使用方法
EP2757161A1 (en) * 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection

Similar Documents

Publication Publication Date Title
CN105530938B (zh) 用于治疗由逆转录病毒引起的疾病的化合物
RU2011149571A (ru) Соединения, пригодные для лечения рака
US20100129320A1 (en) Quinoline derivatives for modulating dna methylation
JP6694476B2 (ja) Aidsを治療する為に有用な化合物
WO2009049132A1 (en) Quinoline derivatives for modulating dna methylation
RU2011149573A (ru) Соединения, пригодные для лечения преждевременного старения и, в частности, прогерии
HK1217447B (zh) 用於治疗由逆转录病毒引起的疾病的化合物
RU2575845C2 (ru) Соединения, пригодные для лечения спида
HK1173726B (en) Compounds useful for treating aids